Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study
Tirzepatide is associated with a lower risk of dementia versus semaglutide and SGLT2-i in type 2 diabetes. Our findings are hypothesis generating, requiring confirmation in randomised controlled trials.
Authors
- David R. J. Riley (ORCID: https://orcid.org/0000-0002-0905-6524)
- Gema Hernández (ORCID: https://orcid.org/0000-0003-4832-455X)
- Li Su (ORCID: https://orcid.org/0000-0002-4136-4770)
- Rayaz Ahmed Malik (ORCID: https://orcid.org/0000-0002-7188-8903)
- Sizheng Steven Zhao (ORCID: https://orcid.org/0000-0002-3558-7353)
- Daniel James Cuthbertson (ORCID: https://orcid.org/0000-0002-6128-0822)
- Uazman Alam
- Matthew Anson
- Alex E. Henney
- Gregory Y.H. Lip
- Alhena Younis
Institutions
- University of Liverpool (GB)
- Manchester Academic Health Science Centre (GB)
- University of Manchester (GB)
- Liverpool Heart and Chest Hospital (GB)
- Weill Cornell Medical College in Qatar (QA)
- TriNetX (United States) (US)
- University of Sheffield (GB)
Publication Details
- Journal
- Diabetes Research and Clinical Practice
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1016/j.diabres.2026.113083
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00